Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Age matched (within 1 year) controls not diagnosed with G1D.
- Ages 1 month to <21 years of age
- Diagnosed with glucose transporter type I deficiency.
- ...
- Age matched (within 1 year) controls not diagnosed with G1D.
- Ages 1 month to <21 years of age
- Diagnosed with glucose transporter type I deficiency.
- Male or Female
Exclusion Criteria
- All subjects carrying body metal implants incompatible with the exposure to a magnetic field
- Patients behaviorally unable to hold still for imaging procedures (rather than limited by seizure activity) will be excluded.
- Subjects receiving oxygen supplementation or those confined to a bed or stretcher
- ...
- All subjects carrying body metal implants incompatible with the exposure to a magnetic field
- Patients behaviorally unable to hold still for imaging procedures (rather than limited by seizure activity) will be excluded.
- Subjects receiving oxygen supplementation or those confined to a bed or stretcher
- Subjects unable to tolerate the MRI and MRS procedures due to anxiety
- Subjects currently receiving a ketogenic diet, due to a high risk of seizure recurrence while transitioning off ketosis.
Summary
- Conditions
- Glucose Transporter Type 1 Deficiency Syndrome
- GLUT1 Deficiency Syndrome
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
Participation Requirements
- Age
- Younger than 120 years
- Gender
- Both males and females
Description
Triheptanoin, a nutritional supplement long used in other metabolic disorders and also added to foods and cosmetics, will be used to complement any diet that G1D patients may be receiving at enrollment with the exception of the ketogenic diet.
Triheptanoin, a nutritional supplement long used in other metabolic disorders and also added to foods and cosmetics, will be used to complement any diet that G1D patients may be receiving at enrollment with the exception of the ketogenic diet.
Inclusion Criteria
- Age matched (within 1 year) controls not diagnosed with G1D.
- Ages 1 month to <21 years of age
- Diagnosed with glucose transporter type I deficiency.
- ...
- Age matched (within 1 year) controls not diagnosed with G1D.
- Ages 1 month to <21 years of age
- Diagnosed with glucose transporter type I deficiency.
- Male or Female
Exclusion Criteria
- All subjects carrying body metal implants incompatible with the exposure to a magnetic field
- Patients behaviorally unable to hold still for imaging procedures (rather than limited by seizure activity) will be excluded.
- Subjects receiving oxygen supplementation or those confined to a bed or stretcher
- ...
- All subjects carrying body metal implants incompatible with the exposure to a magnetic field
- Patients behaviorally unable to hold still for imaging procedures (rather than limited by seizure activity) will be excluded.
- Subjects receiving oxygen supplementation or those confined to a bed or stretcher
- Subjects unable to tolerate the MRI and MRS procedures due to anxiety
- Subjects currently receiving a ketogenic diet, due to a high risk of seizure recurrence while transitioning off ketosis.
Tracking Information
- NCT #
- NCT02018315
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Juan M. Pascual, MD, PhD UT Southwestern Medical Center
- Juan M. Pascual, MD, PhD UT Southwestern Medical Center
Get Well Soon